Stamford, Conn. – Jan. 2, 2014 – Mylan has donated more than $3 million in critically needed medicines to AmeriCares for its Typhoon Haiyan relief efforts in the Philippines. The donation –the Pittsburgh-based global pharmaceutical company’s largest emergency donation to AmeriCares to date – will help thousands of Filipinos suffering with infections, diabetes and cardiovascular diseases to lower the risks of developing debilitating or life-threatening complications.
“After major disasters it can take months before essential medicines are available in the most devastated communities,” said Kate Sears, AmeriCares Senior Vice President of Emergency Response. “With help from dedicated partners like Mylan we are ensuring survivors have access to chronic care medicines that can prevent further tragedy.”
Mylan, which has more than 500 employees in the Pittsburgh metro area, has supported AmeriCares aid deliveries worldwide since 1991.
Mylan CEO Heather Bresch commented: “Mylan, one of the world’s largest generics and specialty pharmaceutical companies, is very pleased to support AmeriCares relief effort in the Philippines. Our mission to provide the world’s 7 billion people with access to high quality medicine is aligned with AmeriCares ongoing efforts to expand access to medicine through distribution to communities in need.”
AmeriCares emergency response team was on the ground in the Philippines within days of the Nov. 8 storm. AmeriCares has been delivering aid to the Philippines since 1985 and supports a network of 150 health care facilities across the country, allowing it to quickly speed relief to disaster survivors. Over the years, the disaster relief and humanitarian aid organization has delivered more than $230 million in aid to the Philippines including relief supplies for survivors of the October earthquake and Typhoon Bopha in 2012.
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com